【礼来(LLY.US)公布口服减肥药orforglipron三期临床数据:最高剂量下40周减重8%!】智通财经APP获悉

智通财经
Jun 23, 2025
【礼来(LLY.US)公布口服减肥药orforglipron三期临床数据:最高剂量下40周减重8%!】智通财经APP获悉,礼来(LLY.US)于上周六公布了其口服小分子GLP-1类药物orforglipron在三期临床试验ACHIEVE-1中的详细数据。数据显示,在所有剂量组中,这款在研药物实现了2型糖尿病成人患者糖化血红蛋白平均1.3%至1.6%的降幅,且在用药四周内就可观察到改善,同时,高剂量组在第40周时实现平均体重减轻近8%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10